SCM
MIRM icon

Stonepine Capital Management’s Mirum Pharmaceuticals MIRM Stock Holding History

Stonepine Capital Management’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-108,769
Closed -$2.12M – 23
2022
Q4 		$2.12M Buy
+108,769
New +$2.15M 0.89% 14

Other funds holding MIRM

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
RVM
RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Stonepine Capital Management's MIRM Position: Q1 2023 in Review

Stonepine Capital Management sold out of Mirum Pharmaceuticals (MIRM) in Q1 2023, closing a stake of 108,769 shares — an estimated $2.12M sold.

Stonepine Capital Management first reported a position in MIRM in Q4 2022 and held it in 1 quarter. The position peaked at $2.12M in Q4 2022. 117 funds tracked by Wall St. Rank hold MIRM as of Q1 2023.

  • Stonepine Capital Management reported no remaining Mirum Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Stonepine Capital Management sold 108,769 Mirum Pharmaceuticals shares in Q1 2023, an estimated $2.12M.
  • Stonepine Capital Management first reported a position in Mirum Pharmaceuticals in Q4 2022 and held it in 1 quarter.
  • Stonepine Capital Management's Mirum Pharmaceuticals position peaked at $2.12M in Q4 2022.
  • 117 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q1 2023.

Based on Stonepine Capital Management's 13F filing for Q1 2023, filed 12 May 2023.